Total mesopancreas excision during surgery for pancreatic head cancer
Tests removing tissue around pancreas vessels during surgery for pancreatic head cancer.
Plain-language title generated from the registry record
Registry title: Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
Key facts
- Where
- Minya, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07232810, who can take part
Where in Egypt
- Liver and GIT hospital , Minia UniversityMinya, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Minia University
- Trial code
- NCT07232810
- Record updated
- 2 December 2025
- Original description
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreaticoduodenectomy for resectable pancreatic head cancer. Secondary objectives include assessing Overall Survival (OS), R0 resection rates, recurrence patterns, and perioperative outcomes in 90 consecutive patients.Read full original descriptionShow less
Prognostic Outcomes of Total Mesopancreas Excision During Pancreaticoduodenectomy for Pancreatic Head Cancer
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreaticoduodenectomy for resectable pancreatic head cancer. Secondary objectives include assessing Overall Survival (OS), R0 resection rates, recurrence patterns, and perioperative outcomes in 90 consecutive patients.
Inclusion: Age ≥18 years; Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision; Histologically confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided biopsy); Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant metastases, no arterial involvement >180°, venous involvement reconstructable); Eastern Cooperative Oncology Group(ECOG) performance status 0-2; Adequate organ function (e.g., bilirubin <1.5x upper limit of normal(ULN), creatinine clearance >50 mL/min); Informed consent.
Exclusion: Prior neoadjuvant chemotherapy or radiotherapy (to isolate TMpE effect;may be amended for subgroups); Patients who have received prior radiotherapy to the abdomen; Active second malignancy; Severe comorbidities precluding surgery (e.g., uncontrolled cardiac disease); Irresectable PDAC; Distant metastases; Periampullary tumors other than pancreatic adenocarcinoma; Pregnancy or lactation; Patients unwilling or unable to provide informed consent.